ADDAX Biosciences proposes a revolution in the fixative market by the introduction of GAF, an innovative reagent that will allow the optimal tissue fixation at structural and molecular level combined with the absence of toxicity and carcinogenic activity, at variance of the fixative in use.
ADDAX Biosciences introduces into the market a histological fixative as alternative to Formalin, a toxic and canginogenic agent, based on an innovative glyoxal solution: Acid Deprived DiAldehyde FiXative (GAF). The results have been published in an international peer reviewed journal (Plos One 12:e0182965; 2017).
The innovative ADDAX Glyoxal (GAF) is protected by an international patent. The annual usage of Formalin can be estimated in more than 1 million liters in Italy. The Total Addressable Market for GAF is around 20 million liters in the World.
ADDAX SOCIAL INNOVATION ROLE
TOWARDS A FORMALIN-FREE HOSPITAL